Lisa Astor | Authors

Lisa Astor is the Associate Editorial Director for Targeted Oncology. Astor received her Bachelor of Arts in English Literature from New York University.


Managing Adverse Reactions in Patients With RCC Treated With Lenvatinib/Pembrolizumab

December 21, 2021

Proactive management of treatment-emergent adverse events, including treatment interruption, may be crucial for patients with renal cell carcinoma receiving lenvatinib in combination with pembrolizumab, according to the CLEAR study investigators.